论文部分内容阅读
评价加速超分割放疗对中、晚期食管瘤的疗效。［方法］自１９９２年１月至１９９３年６月对２４０例中、晚期食管癌 病人进行前瞻性研究。其中加速超分割组（加超组）１１９例，常规分割组（常规组）１２１例。两组中又将病灶长度小于７ｃｍ及大于（等 于）７ｃｍ的患者进行比较，并经统计学处理。［结果］加超组的 １、３、５年生存率为５４．６％、３０．３％、１４．３％；常规组的 １、３、５年生存率 为３５．５％、１７．４％、１０．７％。其中病灶长度小于７ｃｍ食管癌患者，加超组与常规组比较差异不大，而病灶长度大于（等于）７ｃｍ的患 者，加超组的 １、３年生存率与常规组的 １、３年生存率相比较有统计学意义。两组病人放疗的副反应无差异。［结论］加超组对病灶 长度大于（等于）７ｃｍ的晚期食管癌病人能明显提高１、３年生存率，对其远期疗效与常规组比较则无明显差异。
Evaluate the effect of accelerated hyperfractionated radiotherapy on advanced esophageal neoplasms. [Methods] From January 1992 to June 1993, 240 patients with advanced esophageal cancer were prospectively studied. There were 119 cases with accelerated hyperfractionation group (additional super group) and 121 cases with conventional segmentation group (conventional group). In the two groups, patients with a lesion length of less than 7cm and greater than (equal to) 7cm were compared and statistically processed. [Results] The 1-, 3-, and 5-year survival rates of the hyper-group were 54.6%, 30.3%, and 14.3%; the 1-, 3-, and 5-year survival rates of the routine group were 35.5%, 17. 4%, 10.7%. In patients with esophageal cancer whose lesion length is less than 7cm, there is no significant difference between the plus hypergroup and the conventional group, but in patients with a lesion length greater than (equal to) 7cm, the 1-year and 3-year survival rates in the plus-supergroup and the 1- and 3-year survival in the conventional group are not significant. The rate is statistically significant. There was no difference in the side effects of radiotherapy between the two groups of patients. [Conclusion] Hyperchadergic group can significantly improve the 1-year and 3-year survival rate of patients with advanced esophageal cancer whose lesion length is greater than (equal to) 7 cm. There is no significant difference in the long-term efficacy between conventional hyperparathyroidism and conventional group.